COMMUNIQUÉS West-GlobeNewswire

Oxford-Harrington Rare Disease Centre to Host Symposium on Pioneering Research and Innovation in Rare Disease Treatments

24/09/2024 - 10:00

OXFORD, UK and CLEVELAND, Ohio, US, 24 th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals [...]

Communiqué de presse France : Sanofi devient membre fondateur de la Fondation de l’Université Paris-Saclay et apporte son soutien financier dans le cadre d’une convention de mécénat

24/09/2024 - 09:11

Sanofi devient membre fondateur de la Fondation de l’Université Paris-Saclay et apporte son soutien financier dans le cadre d’une convention de mécénat Paris, le 24 septembre 2024. Sanofi et l’Université Paris-Saclay [...]

AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy

24/09/2024 - 09:00

PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, ATX01, announced today the completion [...]

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

24/09/2024 - 09:00

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe [...]

Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia

24/09/2024 - 08:06

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make [...]

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy

24/09/2024 - 08:00

Proceeds will be used to advance the Company’s IMANs into clinical trials Raise underpins strong pre-clinical data demonstrating dual mechanism of action of LIfT’s IMANS London, 24 September 2024– LIfT BioSciences, (‘ [...]

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

24/09/2024 - 07:15

Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]

Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses

24/09/2024 - 07:00

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 [...]

Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy

24/09/2024 - 07:00

Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorization application (MAA [...]

Nature Reviews Highlights Significant Successes of Antibiotic Collaboration and Calls for Sustainable R&D Funding Schemes

24/09/2024 - 07:00

BASEL, Switzerland, Sept. 24, 2024 (GLOBE NEWSWIRE) -- BioVersys AG , a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life- [...]

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24/09/2024 - 07:00

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary endpoints measuring [...]

BioVie Inc. Announces Pricing of Public Offering

24/09/2024 - 04:26

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time

24/09/2024 - 01:10

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO, CA, Sept. 23, 2024 ( [...]

Smart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring Efforts

23/09/2024 - 23:54

Company Files Annual 10-K Report with Full Financial Results MIAMI, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & [...]

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

23/09/2024 - 22:30

Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening process for the [...]

DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE

23/09/2024 - 22:30

Châtillon, France, le 23 septembre 2024 (22 :30 CEST) DBV Technologies clôture le screening des sujets de l'essai clinique de phase 3 VITESSE DBV a dépassé son objectif de recrutement, clôturant avec succès au troisième [...]

BioVie Inc. Announces Proposed Public Offering

23/09/2024 - 22:05

CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and [...]

QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database

23/09/2024 - 22:05

QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration ensures GEDmatch PRO [...]

Comprehensive Urology Studies ED Injections with Shockwave Therapy for Penile Girth Enhancement

23/09/2024 - 21:34

LOS ANGELES, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Comprehensive Urology has opened another round of observational studies for the STUD Protocol for male enhancement as part of their Prostate Cancer Awareness Month events [...]